Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538038 · ClinicalTrials.gov registry record
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
A clinical trial of Non-Small Cell Lung Cancer and Stage IV Lung Cancer, sponsored by PrECOG.
- Recruiting
- Registry status
- 538
- Enrollment target
- 20
- Study locations
NCT06538038: Recruiting study of Non-Small Cell Lung Cancer and Stage IV Lung Cancer, sponsored by PrECOG.
NCT06538038 is a study of Non-Small Cell Lung Cancer and Stage IV Lung Cancer that is actively recruiting participants, run by PrECOG. The registered enrollment target is 538 participants, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06538038, a study of Non-Small Cell Lung Cancer and Stage IV Lung Cancer, is actively recruiting participants, sponsored by PrECOG.
- RECRUITING
- Registry status
- 538 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.
Primary Outcome
Time from initiating therapy to progression or death without documented progression
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Osimertinib + Chemotherapy
Study Locations (20)
Illinois
- Advocate Good Shepherd Hospital - Barrington
- Northwestern University - Chicago
- John H Stroger Jr Hospital of Cook County - Chicago
- Advocate Illinois Masonic Medical Center - Chicago
- Northwestern Medicine Cancer Center Kishwaukee - DeKalb
- Northwestern Medicine Cancer Center Delnor - Geneva
California
- Stanford Cancer Center Emeryville - Emeryville
- Stanford Cancer Institute Palo Alto - Palo Alto
- Stanford Cancer Center South Bay - San Jose
- John Muir Health - Walnut Creek
Arkansas
- Mercy Clinic Fort Smith Communities - Fort Smith
- Mercy Research - Fort Smith
- Fowler Family Cancer Center - Jonesboro - Jonesboro
Georgia
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Liberty County Cancer Care - Hinesville
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Regional Cancer Care - Jesup
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler - Savannah
Delaware
- Bayhealth - Dover
- Satellite of Bayhealth Sussex - Milford
Alabama
- University of Alabama at Birmingham - Birmingham
District of Columbia
- Sibley Johns Hopkins University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2029-08 |
What NCT06538038 shows while recruiting
NCT06538038 is an observational study that tracks outcomes without assigning an intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, below the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (17% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT06538038 names 20 study sites across 7 states, led by Illinois, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06538038 about?
NCT06538038 is a clinical study titled "Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients". The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety ...
What is the current status of trial NCT06538038?
This trial is currently recruiting. The enrollment target is 538 participants. The study started on 2024-09-17. Estimated completion is 2029-08.
What conditions does trial NCT06538038 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage III Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation.
What interventions are being tested in trial NCT06538038?
The interventions under investigation include: Osimertinib (DRUG), Osimertinib + Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT06538038?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06538038 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06538038's enrollment target sits among peer trials
538 68th of 454 higher than 387 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI